We are live on
!
Find out more
EAM
Eventide Asset Management Portfolio holdings
AUM
$6.05B
1-Year Est. Return
76.64%
This Fund
S&P 500
This Quarter
Est. Return
+2.73%
1 Year Est. Return
+76.64%
3 Year Est. Return
+247.17%
5 Year Est. Return
+285.6%
10 Year Est. Return
+2,546.71%
AUM
$7.58B
AUM Growth
+$139M
(+1.9%)
Cap. Flow
+$177M
Cap. Flow
% of AUM
2.33%
Top 10 Holdings %
Top 10 Hldgs %
25.49%
Holding
165
New
14
Increased
52
Reduced
27
Closed
13
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
DICE
DICE Therapeutics, Inc. Common Stock
DICE
|
+$63.7M |
| 2 |
FIVE9
FIVN
|
+$52.6M |
| 3 |
Xometry
XMTR
|
+$50.4M |
| 4 |
Global E Online
GLBE
|
+$32.3M |
| 5 |
Fiverr
FVRR
|
+$31.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$83.1M |
| 2 |
TRIL
Trillium Therapeutics Inc.
TRIL
|
+$50M |
| 3 |
Celldex Therapeutics
CLDX
|
+$46M |
| 4 |
BridgeBio Pharma
BBIO
|
+$43.4M |
| 5 |
RingCentral
RNG
|
+$39.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 34.36% |
| 2 | Technology | 30.11% |
| 3 | Industrials | 12.97% |
| 4 | Consumer Discretionary | 7.19% |
| 5 | Communication Services | 4.5% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
ALX Oncology
ALXO
$262M
| – | – |
-439,950
| Closed | -$24.1M |
|
|
152
BridgeBio Pharma
BBIO
$16.1B
| – | – |
-712,197
| Closed | -$43.4M |
|
153
Equinix
EQIX
$103B
| – | – |
-17,693
| Closed | -$14.2M |
|
154
Keros Therapeutics
KROS
$202M
| – | – |
-427,414
| Closed | -$18.2M |
|
155
Lemonade
LMND
$3.76B
| – | – |
-6,000
| Closed | -$480K |
|
156
MSCI
MSCI
$41.9B
| – | – |
-6,500
| Closed | -$3.46M |
|
157
NXP Semiconductors
NXPI
$61.8B
| – | – |
-11,900
| Closed | -$2.45M |
|
158
Sotera Health
SHC
$5.09B
| – | – |
-870,000
| Closed | -$21.1M |
|
159
ARS Pharmaceuticals
SPRY
$559M
| – | – |
-371,384
| Closed | -$11.5M |
|
160
Xenon Pharmaceuticals
XENE
$6.2B
| – | – |
-1,490,000
| Closed | -$27.7M |
|
|
AYX
161
DELISTED
Alteryx Inc
AYX
| – | – |
-11,000
| Closed | -$1.1M |
|
|
APTO
162
DELISTED
Aptose Biosciences, Inc.
APTO
| – | – |
-5,109
| Closed | -$7.63M |
|
|
MAAC
163
DELISTED
Montes Archimedes Acquisition Corp. Class A Common Stock
MAAC
| – | – |
-700,000
| Closed | -$6.92M |
|
Similar funds
HPG
EMPI
RCG
JWBC
AAM
AA
CM
CIS
Eventide Asset Management's Q3 2021 Portfolio in Review
As of Q3 2021, Eventide Asset Management held 165 positions worth $7.58B, up 1.9% from $7.44B the previous quarter. Its ten largest holdings account for 25% of the portfolio.
Eventide Asset Management's Q3 2021 filing shows 14 new, 52 increased, 27 reduced and 13 closed positions. Its largest new stake was DICE Therapeutics, Inc. Common Stock: 1,871,612 shares worth $59.2M. The largest sale was Biohaven Pharmaceutical Holding Company Ltd., an estimated $83.1M.
By sector, the portfolio is most concentrated in Healthcare at 34% of assets, down from 36% a quarter earlier, followed by Technology and Industrials.
- Eventide Asset Management's largest Q3 2021 buy was DICE Therapeutics, Inc. Common Stock: 1,871,612 shares worth $59.2M.
- Eventide Asset Management added most to FIVE9 in Q3 2021, an estimated $52.6M increase.
- Eventide Asset Management's biggest Q3 2021 reduction was Biohaven Pharmaceutical Holding Company Ltd., cutting an estimated $83.1M.
- Eventide Asset Management fully exited BridgeBio Pharma in Q3 2021, selling an estimated $43.4M.
- Eventide Asset Management's ten largest holdings make up 25% of its $7.58B portfolio in Q3 2021.
- Eventide Asset Management opened 14 new positions and closed 13 in Q3 2021.
- Eventide Asset Management's portfolio value rose 1.9% quarter-over-quarter to $7.58B.
Based on Eventide Asset Management's 13F filing for Q3 2021, filed 15 Nov 2021.